Loyal raises $45 million

Loyal, a biotech startup on a mission to increase the life span of dogs, has raised $45 million in a Series B round led by Bain Capital Ventures. This brings total funding raised by Loyal to more than $125 million and includes a $12 million credit facility from Bridge Bank, part of Western Alliance Bank.

Valor Equity Partners, Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, Quiet Capital, and Todd & Rahul’s Angel Fund also participated in this round.

Founded in 2019, the San Francisco-based startup is developing drugs intended to help dogs live longer, healthier lives by targeting the underlying mechanisms of aging.

Loyal currently has three drugs in development. LOY-001 and LOY-003 are designed to extend the healthy lifespan of large-breed dogs, and LOY-002 is designed for senior dogs 14 pounds and over. The company anticipates that LOY-002 will be available in early 2025, pending FDA conditional approval.

“This fundraise fuels our efforts to bring to market what we hope will be the first FDA-approved drug to extend healthy lifespan. All of our work is centered on giving dogs longer, healthier lives. I’m proud of the work the team has done to date and we have a very important and challenging vision to realize. I’m excited to work with our new and existing investors and continue to make FDA-approved dog longevity drugs a reality.” – Celine Halioua, Founder and CEO of Loyal.

“Celine and her innovative, passionate, and responsible team at Loyal are making fast progress toward approved longevity medicines. For the 65 million households in America with a dog, Loyal’s promise means longer, healthier dog lives – more priceless memories of excited greetings at the door, games of fetch in the park, and cozy afternoons together on the couch.” – Kevin Zhang, Partner at Bain Capital Ventures.